Literature DB >> 12243792

Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases.

Gianluigi Giannelli1, Francesca Pierri, Paolo Trerotoli, Felice Marinosci, Gabriella Serio, Oronzo Schiraldi, Salvatore Antonaci.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. Despite improvements in diagnostic and therapeutic interventions, prognosis and survival are still poor. To identify factors influencing survival, we retrospectively examined 150 consecutive patients with HCC from the time of first diagnosis of cirrhosis to death. In a multivariate analysis, we found that patients with larger HCC lesions had shorter survival, while other pathologic features had no predictive value. The most important and reliable prognostic factor was the occurrence of tumor thrombus of the portal vein (P<0.01). Child's stage of underlying liver disease was relevant only in the univariate, but not in the multivariate analysis. The survival of patients with HCC is mainly affected by the biological ability of cancer cells to invade surrounding tissue and vessels. More studies are needed to elucidate the mechanisms that modulate tumor cell motility, in order to design more effective therapies.

Entities:  

Year:  2002        PMID: 12243792     DOI: 10.1016/s1386-6346(02)00027-x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  12 in total

1.  Caspase-Cleaved Cytokeratin 18 Fragment M30 as a Potential Biomarker of Macrovascular Invasion in Hepatocellular Carcinoma.

Authors:  Hatem Elalfy; Tarek Besheer; Mona M Arafa; Mona Abo-Bakr El-Hussiny; Mahmoud Abd El Latif; Sahar Alsayed Mohamed Alsayed
Journal:  J Gastrointest Cancer       Date:  2018-09

2.  Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma.

Authors:  Wen-Jiao Zeng; Guo-Yuan Liu; Jie Xu; Xin-Da Zhou; Yue-E Zhang; Nong Zhang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

3.  Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation.

Authors:  Zheng-Hua Lu; Feng Shen; Zhen-Lin Yan; Jun Li; Jia-He Yang; Ming Zong; Le-Hua Shi; Meng-Chao Wu
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553

4.  Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.

Authors:  Rosalba D'Alessandro; Maria Grazia Refolo; Catia Lippolis; Nicola Carella; Caterina Messa; Aldo Cavallini; Brian Irving Carr
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

5.  Massive portal vein tumor thrombus from colorectal cancer without any metastatic nodules in the liver parenchyma.

Authors:  Naoto Yamamoto; Nobuhiro Sugano; Soichiro Morinaga; Amane Kanazawa; Daisuke Inagaki; Manabu Shiozawa; Yasushi Rino; Makoto Akaike
Journal:  Rare Tumors       Date:  2011-10-26

6.  Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Jiangguo Zhang; Fengyun Gong; Ling Li; Manzhi Zhao; Jianxin Song
Journal:  Oncol Lett       Date:  2014-02-20       Impact factor: 2.967

7.  Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Yoshinari Asaoka; Ryosuke Tateishi; Ryo Nakagomi; Mayuko Kondo; Naoto Fujiwara; Tatsuya Minami; Masaya Sato; Koji Uchino; Kenichiro Enooku; Hayato Nakagawa; Yuji Kondo; Shuichiro Shiina; Haruhiko Yoshida; Kazuhiko Koike
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 8.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

Review 9.  [Update on chemoinfusion and chemoembolization treatments].

Authors:  A Lubienski; M Simon; K Lubienski; J Gellissen; R-T Hoffmann; T F Jakobs; T Helmberger
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

10.  Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.

Authors:  G Giannelli; A Azzariti; E Fransvea; L Porcelli; S Antonaci; A Paradiso
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.